Praluent is.......

tip of the iceberg for REGN woes............

 

...outta here!!

 

Were the reps let go?

 

not that we know of

 

REGN is shifting manufacturing folks around. No word on reps I know of.

 

Making REGN affordable!

 

toast.
What are reps thinking or being told? I know a few folks there.

 

going going gone!
It always was a beat down to sell. Absolutely no advantages to Rapatha. Horrible name with Sanofi attached to it. Ever meet those Sanofi turds? I avoided them like the plague.

 

I agree the sanofi product is toast but the Amgen reps are the slimiest, most dishonest reps out there. Going thru patient charts, filing out PA paperwork and pretending to be office staff while strong-arming insurance companies for approvals over the phone was just the tip of the iceberg. I saw it with me own eyes.

 

...joke product by joke company who thinks rules and regulations don't apply.

 

foreshadow for Dupi with high cost, low physician uptake, non-existent payer subscription.

 

You know we all did it, otherwise these offices couldn't get it approved! Just glad I'm moving onto the final round of interviews with Radius...

 

Why would Radius want a Regeneron loser and my guess is you probably came from Amgen before Regeneron, correct?

 

This place is contaminated with YES men and YESOH women. Most likely, nobody will hire from this dump!

 

Is the whole CV team gone? DMs, etc?

 

Are you on crack, Praluent is alive and well business as usual at Regeneron, right?

 

For Amgen, sure!

 

Radius is a joke. They're hiring Lilly rejects and a bunch of vaccine reps that don't know what they're doing. Have fun.

 

Big Pharma Hillbilly Style...

"Finally, REGN has invested large sums in a US sales force for Praluent, even though it knew from the start that insurers were going to be highly restrictive on utilization."
Thus, a lot of questions about planning, capital utilization, patent analysis, risk-taking, and pricing of drugs have been raised regarding SNY and REGN.

"While SNY is the senior member of the partnership and may have driven the pricing and product launch decisions, REGN has not publicly indicated any disagreement with any decision, and it was under no obligation to participate in the marketing of Praluent as I understand the deal with SNY. So REGN management must face questions about the various decisions that have worked out so poorly; the company cannot just point to SNY as the boss."

 

Hubris, incompetence and still no accountability. ..